New FDA Breakthrough-Drug Category — Implications for Patients
Authors:
- Jonathan J. DarrowJDJonathan J. Darrow
- Jerry AvornJAJerry Avorn
- Aaron S. KesselheimAKAaron S. Kesselheim
- 27 March 2014
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 370 (13) , 1252-1258
Abstract
U.S. pharmaceutical regulations are based on the principle that patients should not be exposed to new prescription drugs until their efficacy and safety have been shown. Since 1962, the Food and Drug Administration (FDA) and Congress have balanced the efficient review of investigational drugs with the need to withhold judgment until sufficient evidence is available to clarify the benefit–risk relationship. Misjudging these competing interests in either direction causes important problems. On the one hand, the evidentiary hurdles of the FDA are often criticized by pharmaceutical companies and patient advocacy groups for slowing access to promising therapies. On the other hand, truncated premarket review can lead to the approval of drugs that are ineffective, unsafe, or both.Keywords
This publication has 21 references indexed in Scilit:
- Expediting Drug Development — The FDA's New “Breakthrough Therapy” DesignationNew England Journal of Medicine, 2013
- New Drugs and SafetyArchives of internal medicine (1960), 2012
- Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory AgenciesNew England Journal of Medicine, 2012
- The Complications of Controlling Agency Time Discretion: FDA Review Deadlines and Postmarket Drug SafetyAmerican Journal of Political Science, 2011
- Lessons from 60 years of pharmaceutical innovationNature Reviews Drug Discovery, 2009
- Drug-Review Deadlines and Safety ProblemsNew England Journal of Medicine, 2008
- The risk we bear: The effects of review speed and industry user fees on new drug safetyJournal of Health Economics, 2008
- Bolstering the FDA's Drug-Safety AuthorityNew England Journal of Medicine, 2007
- THE PRESCRIPTION DRUG USER FEE ACT OF 1992 AND THE NEW DRUG DEVELOPMENT PROCESSAmerican Journal of Therapeutics, 1997
- The Prescription Drug User Fee Act of 1992PharmacoEconomics, 1996